NEED TO KNOW

• Cleveland Clinic study links GLP-1 use to lower cancer progression in four tumor types
• Largest effects: 50% reduction in lung, 43% in breast cancer progression to stage 4
• Findings are observational, unpublished, and cannot prove cause and effect

CLEVELAND, OH (TDR) — Patients who started a GLP-1 drug after a cancer diagnosis were significantly less likely to progress to metastatic disease across four obesity-related cancers, according to Cleveland Clinic research set for presentation at the American Society of Clinical Oncology annual meeting next week.

The big picture: The study is the largest real-world signal to date that GLP-1 receptor agonists, the class that includes Ozempic, Wegovy, and Mounjaro, may do more than control blood sugar and reduce weight.

Freedom-Loving Beachwear by Red Beach Nation - Save 10% With Code RVM10

• Researchers tracked 10,225 patients with stage 1–3 cancer who started a GLP-1 after diagnosis
• Each was propensity-matched to a patient on DPP-4 inhibitors (gliptins), a separate diabetes drug class
• Cancers covered: breast, prostate, lung, colorectal, liver, kidney, pancreatic

Why it matters: Roughly 1 in 8 American adults has taken a GLP-1 drug, and that population overlaps heavily with cancer risk groups: older, heavier, and frequently diabetic patients.

• Lung cancer progression to stage 4: 10.0% on GLP-1 vs. 22.3% on gliptins
• Breast cancer progression: 10.2% vs. 20.1%
• Colorectal and liver cancers also showed statistically significant reductions

Driving the news: Lead author Dr. Mark Orland said the benefits appear independent of weight loss or diabetes control.

CLICK HERE TO READ MORE FROM THE THE DUPREE REPORT

• Patients were matched for age, race, BMI, comorbidities, and cancer treatments
• Three cancers (prostate, kidney, pancreatic) showed no statistically significant benefit
• Data pulled from the TriNetX Global Health Research Network spanning 150 million patient records
• The four cancers that showed benefit all have documented GLP-1 receptor expression in tumor tissue, suggesting a plausible biological pathway

What they're saying:

• Mark Orland, MD, Cleveland Clinic Taussig Cancer Institute — "Our study found that use of GLP-1 drugs, compared to DPP-4 inhibitors and other antidiabetic drugs, was associated with a meaningful reduction in cancer progression across four solid tumor types."
• Orland, on mechanism — "Cancers are part of a complex ecosystem, the body."
• ASCO Post, on the limits — "Because the analysis was observational, the results cannot prove that GLP-1 RAs directly reduced metastatic progression."

Yes, but: The skeptic case has gotten weaker, not stronger, but the evidence still isn't there to call this proven.

• The study has not been peer-reviewed and the abstract has not been presented yet
• Black-box warnings for medullary thyroid cancer remain on every GLP-1 label, based on rat data
• Earlier FAERS-based signals raised concerns about pancreatic and thyroid cancer that subsequent long-term trials have largely failed to confirm
• Effect sizes this large in observational data often shrink in randomized trials, where the gap between "associated with" and "causes" tends to close

Between the lines: The political and commercial pressure on this data is enormous, and it cuts in opposite directions. GLP-1 makers face an active federal review of long-term effects under the current HHS, while ASCO presentations move pharma stocks within hours. A finding this favorable, this early, lands in a market primed to overread it, and a regulatory environment looking for reasons to be skeptical. The science deserves randomized trials before either side gets to claim the verdict.

What's next:

• Abstract presentation at the ASCO Annual Meeting May 29–June 2 in Chicago
• Orland's team has proposed randomized controlled trials in cancer patients
• Mechanistic studies underway examining tumor metabolism, immune effects, and inflammation pathways
• Peer-reviewed publication still pending

If a drug that 1 in 8 Americans already takes turns out to slow cancer, what should the evidence threshold be — and who decides we've cleared it?

Sources

This report was compiled using reporting from ASCO, The ASCO Post, NBC News, Targeted Oncology, Oncology Central, and the Journal of Clinical Investigation

Freedom-Loving Beachwear by Red Beach Nation - Save 10% With Code RVM10